DiaMedica Therapeutics
DMAC
34 hedge funds and large institutions have $10M invested in DiaMedica Therapeutics in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 6 closing their positions.
80% more call options, than puts
Call options by funds: $157K | Put options by funds: $87K
0.05% more ownership
Funds ownership: 15.11% → 15.16% (+0.05%)
13% less funds holding
Funds holding: 39 → 34 (-5)
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
33% less capital invested
Capital invested by funds: $14.9M → $10M (-$4.88M)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CLG
Cooperman Leon G
|
+$1.45M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$131K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$34.5K |
| 4 |
Morgan Stanley
New York
|
+$27K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$540K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$485K |
| 3 |
Two Sigma Investments
New York
|
-$258K |
| 4 |
Two Sigma Advisers
New York
|
-$162K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$96K |
DMAC Hedge Fund Activity: Q1 2022 in Review
34 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q1 2022, worth a combined $10M — down 33% from $14.9M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of DMAC and 1 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 9 added.
The largest buyer was Cooperman Leon G, adding an estimated $1.45M. The largest seller was Manatuck Hill Partners, exiting entirely with an estimated $540K sold.
- 34 institutional investors held DiaMedica Therapeutics (DMAC) as of Q1 2022, down from 39 in Q4 2021.
- Funds reported $10M of DiaMedica Therapeutics stock for Q1 2022, down 33% quarter-over-quarter.
- 1 fund opened new DiaMedica Therapeutics positions in Q1 2022 and 6 closed out, a net change of -5 holders.
- The largest DiaMedica Therapeutics buyer in Q1 2022 was Cooperman Leon G, an estimated $1.45M added.
- The largest DiaMedica Therapeutics seller in Q1 2022 was Manatuck Hill Partners, an estimated $540K sold.
Based on aggregated 13F filings for Q1 2022.